Surely everyone has seen the news of the new proposal to return NIH budgets to 2008 levels. Calls for those of us in the public sector research enterprise to call or write our Congress Critters are coming from all of our professional organizations right now. If you’re going to call or write your rep, it might be worthwhile to have some numbers in hand to remind that staffer of the impact of NIH research. We all talk about impact on health outcomes, etc., and maybe some of us talk about economic impact of NIH investment but the role of NIH research in private sector development has been harder to pin down (and some of the previous adversarial industry vs. academia spats have not helped). A major argument I have heard from Republicans is that while NIH research is nice and all, the main driver for health care innovation is the private sector. The primary innovation area is widely viewed as pharmaceutical development. This brand spanking new NEJM paper throughs a serious wrench into that argument.
For the too lazy to click crowd, here is a pretty table from the paper:
My favorite part of this, and the argument I am going to use, is that new indications for existing drugs is coming almost entirely from public sector research. There are serious cost savings opportunities to be found going this route and FDA approvals for new indications is just the tip of the iceberg.
Unfortunately for me, my rep, who is almost always responsive to these things, is not able to do the job she has done so terrifically for the past several years right now. I have a feeling, though, that her friends, family and staff can be counted on for strong NIH funding support so I’m gonna ring up the local office.